A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects This work was previously published as abstracts presented at AAIC 2013 Conference Boston

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 1, Issue 3, 2015, Pages 182-195

  Lues, Inge ^a   Weber, Frank ^a   Meyer, Antje ^a   Bühring, Uli ^a   Hoffmann, Torsten ^a   Kühn Wache, Kerstin ^a   Manhart, Susanne ^a   Heiser, Ulrich ^a   Pokorny, Rolf ^b   Chiesa, Joseph ^c   Glund, Konrad ^a  

^a PROBIODRUG AG   (Germany)

^b Covance Clinical Research Unit AG ^*  (Switzerland)

^c 206 Carnegie Center   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid beta; Cerebrospinal fluid; Glutaminyl cyclase; pE A ; Pyroglutamate; QC inhibitor

Indexed keywords

ENZYME; ENZYME INHIBITOR; GLUTAMINYL CYCLASE; PLACEBO; POTASSIUM; PQ 912; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; CONTUSION; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; EYE DISEASE; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; IN VIVO STUDY; INJECTION SITE PAIN; LEUKOCYTE; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NAUSEA; NECK PAIN; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLLAKISURIA; POTASSIUM BLOOD LEVEL; PRESYNCOPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING;

EID: 84951092250     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2015.08.002     Document Type: Article

References (31)

1. R. Black, I. Lues, F. Weber, A. Meyer, T. Hoffman, R. Pokorny, and et al. Safety, pharmacokinetics and pharmacodynamics of PQ912, the first glutaminyl cyclase (QC) inhibitor to treat Alzheimer's disease, in healthy elderly subjects Alzheimers Dement 9 supplement 2013 280
2. Weber F, Lues I, Meyer A, Hoffmann T, Pokorny R, Lopez L, et al. A phase 1 study assessing safety, pharmacokinetics and pharmacodynamics of PQ912, the first glutaminyl cyclase (QC) inhibitor to treat AD. International conference on Alzheimer's and Parkinson's disease 2013; abstract 1453.
3. J. Cummings, R. Reynders, and K. Zhong Globalization of Alzheimer's disease clinical trials Alzheimers Res Ther 3 2011 24
4. L. Ghezzi, E. Scarpini, and D. Galimberti Disease-modifying drugs in Alzheimer's disease Drug Des Devel Ther 7 2013 1471 1478
5. J.A. Hardy, and G.A. Higgins Alzheimer's disease: The amyloid cascade hypothesis Science 256 1992 184 185
6. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics Science 297 2002 353 356
7. K. Liu, I. Solano, D. Mann, C. Lemere, M. Mercken, J. Trojanowski, and et al. Characterization of Aß11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: Implication of the N-terminally truncated Aβ species in the pathogenesis of Alzheimer's disease Acta Neuropathol 112 2006 163 174
8. T. Iwatsubo, D. M Mann, A. Odaka, N. Suzuki, and Y. Ihara Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome Ann Neurol 37 1995 294 299
9. S. Schilling, T. Hoffmann, S. Manhart, M. Hoffmann, and H.-U. Demuth Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions FEBS Lett 563 2004 191 196
10. S. Schilling, U. Zeitschel, T. Hoffmann, U. Heiser, M. Francke, A. Kehlen, and et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Aß and Alzheimer's disease-like pathology Nat Med 14 2008 1106 1111
11. A. Stephan, M. Wermann, A. von Bohlen, B. Koch, H. Cynis, H.-U. Demuth, and et al. Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics FEBS J 276 2009 6522 6536
12. O. Wirths, T. Bethge, A. Marcello, A. Harmeier, S. Jawhar, P.J. Lucassen, and et al. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases J Neural Transm 117 2010 85 96
13. M. Morawski, M. Hartlage-Rübsamen, C. Jäger, A. Waniek, S. Schilling, C. Schwab, and et al. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Aß pathology in Alzheimer's disease Acta Neuropathol 120 2010 195 207
14. M. Morawski, S. Schilling, M. Kreuzberger, A. Waniek, C. Jager, B. Koch, and et al. Glutaminyl cyclase in human cortex: Correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease J Alzheimers Dis 39 2014 385 400
15. A.P. Gunn, C.L. Masters, and R.A. Cherny Pyroglutamate-Aß: Role in the natural history of Alzheimer's disease Int J Biochem Cell Biol 42 2010 1915 1918
16. L. De Kimpe, A. Bennis, R. Zwart, E.S. van Haastert, J.J. Hoozemans, and W. Scheper Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro PLoS One 7 2012 9
17. C. Russo, E. Violani, S. Salis, V. Venezia, V. Dolcini, G. Damonte, and et al. Pyroglutamate-modified amyloid beta-peptides-AbetaN3(pE)-strongly affect cultured neuron and astrocyte survival J Neurochem 82 2002 1480 1489
18. D. Schlenzig, R. Rönicke, H. Cynis, H.-H. Ludwig, E. Scheel, K. Reymann, and et al. N-Terminal pyroglutamate formation of Aß38 and Aß40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation J Neurochem 121 2012 774 784
19. T.C. Saido Alzheimer's disease as proteolytic disorders: Anabolism and catabolism of beta-amyloid Neurobiol Aging 19 1998 S69 75
20. C. D'Arrigo, M. Tabaton, and A. Perico N-terminal truncated pyroglutamyl amyloid peptide Aβpy3-42 shows a faster aggregation kinetics than the full-length Aβ1-42 Biopolymers 91 2009 861 873
21. J.O. Matos, G. Goldblatt, J. Jeon, B. Chen, and S.A. Tatulian Pyroglutamylated amyloid-β peptide reverses cross β-sheets by a prion-like mechanism J Phys Chem B 118 2014 5637 5643
22. N. Sun, R. Hartmann, J. Lecher, M. Stoldt, S.A. Funke, L. Gremer, and et al. Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-β using NMR spectroscopy J Pept Sci 18 2012 691 695
23. K.L. Viola, and W.L. Klein Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis Acta Neuropathol 129 2015 183 206
24. S. Jawhar, O. Wirths, S. Schilling, S. Graubner, H.-U. Demuth, and T.A. Bayer Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Aβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice J Biol Chem 286 2011 4454 4460
25. H. Song, Y. J Chang, M. Moon, S.K. Park, P.-T. Tran, V.-H. Hoang, and et al. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of γ-secretase activity J Alzheimers Dis 43 2015 797 807
26. K.F. Huang, Y.L. Liu, W.J. Cheng, T.P. Ko, and A.H. Wang Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation Proc Natl Acad Sci U S A 102 2005 13117 13122
27. S. Schilling, T. Hoffmann, M. Wermann, U. Heiser, C. Wasternack, and H.-U. Demuth Continuous spectrometric assays for glutaminyl cyclase activity Anal Biochem 303 2002 49 56
28. A. Gontsarova, E. Kaufmann, H. Tumani, A. Dressel, F. Mandel, K.H. Wiesmüller, and et al. Glutaminyl cyclase activity is a characteristic feature of human cerebrospinal fluid Clin Chim Acta 389 2008 152 159
29. M. T Valenti, S. Bolognin, C. Zanatta, L. Donatelli, G. Innamorati, M. Pampanin, and et al. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer disease patients J Alzheimers Dis 34 2013 263 271
30. J. M Nussbaum, S. Schilling, H. Cynis, A. Silva, E. Swanson, T. Wangsanut, and et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-ß Nature 485 2012 651 655
31. J.H. Lin CSF as a surrogate for assessing CNS exposure: An industrial perspective Curr Drug Metab 9 2008 46 59